Background: The classification of B-lineage acute lymphoblastic leukemia (ALL) by specific chromosomal translocations has prognostic implications for risk-directed therapy. Reverse transcription-polymerase chain reaction (RT-PCR) assay is a useful tool for detecting fusion transcripts from common chromosomal translocations of ALL cells.
C hildhood acute lymphoblastic leukemia (ALL) is a highly heterogeneous disease with distinct biologic subgroups that have different event-free survival rate (EFS) ranging from 30% to 40% in cases with BCR-ABL1 or MLL-AF4 fusion genes to 90% in those with ETV6-RUNX1 fusion. 1, 2 In precursor-B (pre-B) ALL, such significant prognostic genetic abnormalities can be identified in more than 60% of cases. 3 Even with advances in molecular biology and new molecular markers such as gene expression profiles, [4] [5] [6] [7] [8] [9] [10] recurrent chromosomal abnormalities are still the most important prognostic factors and risk factors for different protocol assignments. 2 Although conventional cytogenetics is the standard method for identifying chromosomal translocations, it requires considerable expertize. This results either in false negatives or in noninterpretable results in a large number of cases, especially in laboratories lacking experience in handling karyotyping of malignant cells. The most common ETV6-RUNX1 cannot be identified by routine cytogenetic study.
, T-cell ALL, lymphoblastic lymphoma with lymphoblasts greater than 25% in the bone marrow, hypodiploidy, HR patients with poor treatment response, and presence of BCR-ABL1, MLL-AF4, or other MLL rearrangements in pre-B ALL.
The risk-directed Taiwan Pediatric Oncology Group (TPOG) protocols consisted of multiple chemotherapeutic agents of different intensities. The treatment protocol was upgraded if complete remission was not achieved after initial induction therapy. Events were defined as any relapse or secondary malignancy. Patients or their parents provided informed consent before sample collection. The TPOG-2002-ALL protocols were described in detail elsewhere. 14 
Laboratory Methods
Mononuclear cells were collected from the bone marrow or peripheral blood by density centrifugation using FicollHypaque according to standard methods. Cells were resuspended in Roswell Park Memorial Institute 1640 medium containing 10% heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, and 10% dimethyl sulfoxide, and frozen in liquid nitrogen for long-term storage. Total RNA was extracted with Trizol reagent (Invitrogen, Paisley, UK) according to the manufacturer's instructions, and was then subjected to DNase I treatment.
After RNA extraction, multiplex RT reaction for patients' samples was performed by the method of Scurto et al 12 with slight modifications. For each sample, 1 mg RNA, diethyl pyrocarbonate-treated water, and specific 3 0 oligonucleotide primers for BCR-ABL1, MLL-AF4, TCF-PBX1, and ETV6-RUNX1 with final concentrations of 0.2 mM were heated at 651C for 5 minutes and then placed in ice bath. RNA was then reverse transcribed in a final volume of 10.1 mL containing reverse transcriptase, buffer, deoxyribonucleotide triphosphates (dNTPs), dithiothreitol, and RNAsin. Tubes were incubated for 421C for 1.5 hours.
Multiplex PCR was performed in a final volume of 25 mL containing 5 mL cDNA (5 mg), 0.8 mM dNTPs, 1 Â PCR buffer, 0.1 U Tag, and a combination of 0.2 mM 3 0 and 0.2 mM 5 0 oligonucleotide primers sets for BCR-ABL1, MLL-AF4, TCF-PBX1, and ETV6-RUNX1 on a thermal cycler (ABI 9600) using a touchdown program. The sequences of primers were according to those of Scurto et al. 12 After an initial denaturing step at 941C for 5 minutes, a 3-step PCR (941C for 1 min, 601C for 2 min, followed by 721C for 2 min) was performed for 40 cycles. After amplification, 10 mL of PCR product was run on 3% agarose gel stained with ethidium bromide and visualized under ultraviolet lamp (Fig. 1A) . BCR-ABL1, MLL-AF4, and TCF-PBX1 were visualized after this PCR reaction.
Another nested PCR was performed to amplify the ETV6-RUNX1. PCR was performed in a final volume of 25 mL containing 2.5 mL of the first PCR product, 0.8 mM dNTPs, 0.2 mM t(12;21)3 0 , 0.2 mM t(12;21)5 0 A, 1 Â PCR buffer, and 0.1 U Tag. Samples were amplified at 941C for 5 minutes; 1 cycle at 941C for 1 minute, 551C for 2 minutes, and 721C for 2 minutes for 35 cycles. After amplification, 10 mL of PCR product was run on 3% agarose gel stained with ethidium bromide and visualized under ultraviolet lamp (Fig. 1B) .
Cytogenetics
Bone marrow cells were harvested directly or after 1 to 3 days of unstimulated culture as described earlier. 15 Metaphase chromosomes were banded by trypsin-Giemsa technique and karyotyped according to the International System for Human Cytogenetic Nomenclature.
Statistical Methods
Comparison of baseline clinical variables across groups was made using Fisher exact test for categorical data. A P value less than 0.05 (2-sided) was considered significant.
Patients analyzed for chromosomal abnormalities were initially divided into 6 groups according to their cytogenetic changes. These were t(12;21), t(1;19), t(9;22), MLL gene rearrangement, hyperdiploidy, and others. Overall survival (OS) was calculated using the KaplanMeier method, whereas the log-rank test was used to compare differences between survival curves. OS was measured from the protocol commencement date until the date of death regardless of cause, excluding patients who were alive on their last follow-up. EFS was measured from the date of attaining complete remission until the date of event. Patients who did not achieve complete remission were considered to have an EFS of 0. Patients with no report of relapse by the end of follow-up were included in a census based on the date of last follow-up. EFS and OS were estimated by the Kaplan-Meier method and compared with the Mantel-Haenszel test.
Cox proportional hazard models were constructed for EFS and OS. The covariates included in the full model of OS and EFS were sex, WBC ( <10,000, 10,000 to 50,000, 50,000 to 100,000, and >100,000/mL), age ( <1, between 1 and 10, and >10 y), hospital, and genetic subtypes.
Stepwise backward selection was performed. All calculations were carried out using the SAS software package, version 9 (SAS Inc).
RESULTS

Multiplex PCR Assay
In the 146 cases with childhood B-lineage ALL, 26 (17.6%) had ETV6-RUNX1 fusion transcript, 6 (4%) TCF-PBX1 fusion transcript, 2 (1%) MLL-AF4 fusion transcript, and 12 (8%) ALL-type BCR-ABL1 fusion transcript. Representative cases analyzed by the multiplex assay and detected by gel electrophoresis were shown in Figure 1 .
As expected, none of the 26 cases with ETV6-RUNX1 fusion transcript was identified cytogenetically. However, 5 of the 8 with BCR-ABL studied cytogenetically had the t(9;22). Both cases with MLL-AF4 studied by cytogenetics had detectable t(4;11), whereas all 6 with TCF-PBX1 had the t(1;19).
Patient Characteristics
The clinical characteristics of patients at the time of diagnosis are presented in Table 1 . The median age among the 146 patients (78 boys and 70 girls) was 6.66 years (range: 0 to 17 y) and their median leukocyte count 10 9 (cells/L) was 20.0 (range: 0.2 to 1826). The numbers of SR, HR, and VHR patients were 55, 52, and 41, respectively. The clinical presenting features including age, sex, and initial WBC counts were not statistically different from a larger cohort reported from TPOG recently.
14 However, the numbers of VHR patients of this smaller cohort are larger than that of the original cohort. In addition, more patients with t(9;22) were detected in this cohort and this might be because of the smaller case numbers or lack of full screenings of fusion transcripts for the original cohort.
Biologic Factors of Leukemic Cells Associated With EFS and OS
Patients with ETV6-RUNX1 fusion, hyperdiploidy, and t(1;19)/TCF-PBX1 fusion had the most favorable outcomes, whereas those with the t(9;22)/BCR-ABL1 (Fig. 2) . In multivariable regression analyses examining the association of EFS with cytogenetic changes, other known prognostic factors and treatment groups (Table 1) such as BCR-ABL1 status, WBC counts greater than 100,000/mL, and the VHR group were significantly associated with EFS. BCR-ABL1 status, MLL gene rearrangement, and the VHR group were significantly associated with OS (Table 2 ).
ETV6-RUNX1 had Better EFS and OS but not Independent Prognostic Factor
The EFS and OS were analyzed for patients with or without ETV6-RUNX1. Patients' characteristics are listed in Table 3 (Fig. 3) .
In multivariable regression analyses examining the association of EFS with ETV6-RUNX1 status and other known prognostic factors and treatment groups (Table 1) , none of the following were statistically significant predictors of outcome: ETV6-RUNX1 status, sex, age, and WBC counts. When controlling for other significant predictors of EFS in the final model, the VHR group (P<0.001), but not ETV6-RUNX1 status (P=0.174), was significantly associated with EFS.
BCR-ABL1 was Associated With Very Poor EFS and OS
Patients with BCR-ABL1 (n=12) had inferior EFS (25.40±15.47 vs. 83.03±3.73) (n=136) and OS (28.57± 15.69 vs. 87.75±3.23) than patients without BCR-ABL1 (all P<0.001). In multivariable regression analyses examining the association of EFS with BCR-ABL1 status and the other known prognostic factors and treatment groups (Table 1) , BCR-ABL1 status, WBC counts more than 100,000/mL, and VHR group were significantly associated with EFS. Cox regression revealed that t(9;22) was the independent prognostic factor.
MLL-AF4 and Other MLL Gene Rearrangement Were Associated With Very Poor OS
Patients with MLL-AF4 or other MLL had inferior EFS and OS than patients without MLL-AF4 or other 
Treatment Outcomes by Genotypes of Other International Groups
In this February issue of Leukemia, an international representation of study groups reported and compared the long-term results of patients treated between 1985 and 2007.
14, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] We listed the treatment results of these major childhood ALL study groups and one St Jude report in 2009 according to the genotypes if data were available (Table 4) . 30 As expected, patients with ETV6-RUNX1 have good EFS and OS. BCR-ABL1, MLL-AF4, or other MLL gene rearrangements were poor prognostic genotypes. The prognosis for patients with TCF3-PBX1 improved gradually. In addition, the frequency of ETV6-RUNX1 fusion in our study is lower than that (B25%) in western countries. Although our sample size was relatively smaller, our treatment results for patients with ETV6-RUNX1 and TCF3-PBX1 were quite good in comparison with other groups.
DISCUSSION
This study shows the feasibility of multiplex PCR to screen 4 common fusion transcripts in B-cell ALL. As expected, the RT-PCR can detect t(12;21), which is not detected during routine cytogenetic study. However, some patients with t(9;22) cannot be diagnosed by the first cytogenetic study. Thus, the RT-PCR can add diagnostic accuracy to the cytogenetic study, partly because some patients have no mitotic cells to be analyzed. The biologic factors of leukemic cells are associated with EFS and OS. Patients with ETV6-RUNX1 fusion, hyperdiploidy, and TCF-PBX1 fusion have the most favorable outcomes, whereas those with the BCR-ABL fusion and MLL gene rearrangement have poor prognosis.
The t(12;21) is a submicroscopic rearrangement that cannot be detected during routine cytogenetic study. 11 This abnormality is very important in terms of prognosis. 11, [31] [32] [33] [34] Patients with ETV6-RUNX1 have good long-term treatment outcomes, although some studies show late-relapse in this group of patients or fail to identify this as an independent prognostic factor when considering onset age and initial WBC count. 32, [35] [36] [37] [38] Patients with ETV6-RUNX1 have better EFS (P=0.163) and OS (P=0.028). However, multivariable regression analyses fail to show the ETV6-RUNX1 status as an independent prognostic factor. With improved EFS for B-lineage cases, the favorable prognostic impact of ETV6-RUNX1 fusion is less noticeable. In addition, the frequency of ETV6-RUNX1 fusion in Taiwan, which is 18% to 19% in B-lineage ALL and in some Asian countries, is consistently lower than that (B25%) in western countries. [39] [40] [41] [42] Careful epidemiologic studies are needed to determine these genetic differences of leukemic genetics.
The other important prognostic chromosomal translocation is BCR-ABL1. Although the overall outcome for ALL children has improved, the cure rate for specific VHR subgroups, including those with BCR-ABL1 ALL, are disappointing. Several patients have not been detected to have this translocation upon diagnosis. Clinically, some patients are noted to have this translocation because of relapses despite normal initial chromosomal screening.
Recently, Schultz et al 43 highlighted that imatinib (340 mg/m 2 /d) plus intensive chemotherapy improved 3-year EFS in children and adolescents with BCR-ABL1 ALL, with no appreciable increase in toxicity. Stem cell transplantation plus imatinib offered no advantage over transplantation alone. Although additional follow-up is required to determine the impact of this treatment on long-term EFS and to determine whether chemotherapy plus imatinib can replace bone marrow transplant, this study further highlights the importance of fusion transcript screening through molecular methods so that patients with BCR-ABL1-positive ALL can benefit from intensified or alternative therapies with imatinib as early as possible.
The MLL gene is located at 11q23. 44 MLL is found in 73 different translocations and 54 partner genes have been cloned. 45 The MLL-AF4 ALL is the most common subtype, accounting for 50% of ALL cases in infants and 2% in children. It is also associated with steroid resistance and poor outcome, even with stem cell transplantation. 1, 44 This assay cannot detect each of the HR-associated MLL fusion transcripts that result from translocations affecting 11q23. As most of these rearrangements occur in infants, and in this group of patients the t(4;11) accounts for greater than 80% of lesions, this assay should serve as a useful screening for prognostic markers. Currently available drugs will not enable cure for all infants with ALL, particularly those with MLL rearrangements. Therefore, future innovative strategies are warranted to direct against novel therapeutic targets.
In conclusion, multiplex PCR is a good method to screen the 4 important fusion transcripts. This can complement cytogenetic study and guide risk-directed therapy in childhood ALL.
